

Neil H Bander

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9403632/publications.pdf>

Version: 2024-02-01

45
papers

4,577
citations

218381

26
h-index

253896

43
g-index

48
all docs

48
docs citations

48
times ranked

4809
citing authors

#	ARTICLE	IF	CITATIONS
1	The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. <i>Nature Communications</i> , 2014, 5, 5383.	5.8	522
2	M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Advanced Transitional Cell Carcinoma of the Urothelium. <i>Journal of Urology</i> , 1988, 139, 461-469.	0.2	517
3	Phase I Trial of ¹⁷⁷ Lutetium-Labeled J591, a Monoclonal Antibody to Prostate-Specific Membrane Antigen, in Patients With Androgen-Independent Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 4591-4601.	0.8	468
4	Phase II Study of Lutetium-177 ¹⁷⁷ Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 5182-5191.	3.2	370
5	Phase I Trial of Yttrium-90 ⁹⁰ Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Androgen-Independent Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 2522-2531.	0.8	290
6	Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. <i>International Journal of Cancer</i> , 1993, 55, 96-101.	2.3	228
7	Vascular Targeted Therapy With Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2007, 25, 540-547.	0.8	208
8	Na,K-ATPase β -Subunit Is Required for Epithelial Polarization, Suppression of Invasion, and Cell Motility. <i>Molecular Biology of the Cell</i> , 2001, 12, 279-295.	0.9	180
9	A Phase I/II Study for Analytic Validation of ⁸⁹ Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5277-5285.	3.2	163
10	Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. <i>Seminars in Oncology</i> , 2003, 30, 667-676.	0.8	146
11	⁸⁹ Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2093-2105.	3.3	130
12	Clinical Use of Monoclonal Antibody HuJ591 Therapy: Targeting Prostate Specific Membrane Antigen. <i>Journal of Urology</i> , 2003, 170, S84-8; discussion S88-9.	0.2	122
13	Technology Insight: monoclonal antibody imaging of prostate cancer. <i>Nature Reviews Urology</i> , 2006, 3, 216-225.	1.4	119
14	Prostate-Specific Membrane Antigen as a Potential Novel Vascular Target for Treatment of Glioblastoma Multiforme. <i>Archives of Pathology and Laboratory Medicine</i> , 2011, 135, 1486-1489.	1.2	101
15	Phase 1/2 study of fractionated dose lutetium-177 ¹⁷⁷ labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (¹⁷⁷ Lu-J591) for metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2019, 125, 2561-2569.	2.0	100
16	MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma. , 1997, 33, 233-239.		85
17	A Prospective Pilot Study of ⁸⁹ Zr-J591/Prostate Specific Membrane Antigen Positron Emission Tomography in Men with Localized Prostate Cancer Undergoing Radical Prostatectomy. <i>Journal of Urology</i> , 2014, 191, 1439-1445.	0.2	73
18	Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using ⁹⁰ Y- and ¹⁷⁷ Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. <i>Journal of Nuclear Medicine</i> , 2005, 46, 850-8.	2.8	68

#	ARTICLE	IF	CITATIONS
19	The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase-polymerase chain reaction assay for MN/CA9. , 1999, 86, 492-497.		64
20	Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. EJNMMI Research, 2015, 5, 28.	1.1	63
21	Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers. Cancer and Metastasis Reviews, 1999, 18, 483-490.	2.7	61
22	Antibodyâ€“Drug Conjugate Target Selection: Critical Factors. Methods in Molecular Biology, 2013, 1045, 29-40.	0.4	43
23	Circulating Tumor Cells from Prostate Cancer Patients Interact with E-Selectin under Physiologic Blood Flow. PLoS ONE, 2013, 8, e85143.	1.1	40
24	Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 530.e15-530.e21.	0.8	38
25	Microtubule inhibitor-based antibody–drug conjugates for cancer therapy. OncoTargets and Therapy, 2014, 7, 2227.	1.0	36
26	Meeting report from the Prostate Cancer Foundation PSMAâ€“directed radionuclide scientific working group. Prostate, 2018, 78, 775-789.	1.2	35
27	Bone Marrow Recovery and Subsequent Chemotherapy Following Radiolabeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Men with Metastatic Castration-Resistant Prostate Cancer. Frontiers in Oncology, 2013, 3, 214.	1.3	33
28	Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling. EJNMMI Research, 2016, 6, 7.	1.1	32
29	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. , 2016, 4, 92.		31
30	Phase I trial of docetaxel plus lutetium-177-labeled antiâ€“prostateâ€“specific membrane antigen monoclonal antibody J591 (177Luâ€“J591) for metastatic castrationâ€“resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 848.e9-848.e16.	0.8	29
31	Pilot Study of Hyperfractionated Dosing of Lutetium-177â€“Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (177Lu-J591) for Metastatic Castration-Resistant Prostate Cancer. Oncologist, 2020, 25, 477-e895.	1.9	26
32	A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2642-2651.	3.3	26
33	Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer. Frontiers in Oncology, 2021, 11, 630589.	1.3	26
34	Monoclonal antibodies in urologic oncology. Cancer, 1987, 60, 658-667.	2.0	22
35	Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. Prostate, 2020, 80, 1273-1296.	1.2	16
36	Prostatic irradiation-induced sexual dysfunction: a review and multidisciplinary guide to management in the radical radiotherapy era (Part I defining the organ at risk for sexual toxicities). Reports of Practical Oncology and Radiotherapy, 2020, 25, 367-375.	0.3	14

